^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma

Published date:
09/01/2020
Excerpt:
We observed that APG-2575 in combination with ibrutinib exhibited synergistic growth inhibition on BCL-2-overexpressing or BCL-2-intermediate and MCL-1-overexpressing cell lines OCI-LY8, OCI-LY1, and SU-DHL4...The combination of APG-2575 and ibrutinib significantly induced apoptosis compared with either drug alone, suggesting significant lethality of the combination.
DOI:
10.3727/096504020X15825405463920